10-Q: Cardiff Lexington Reports Q2 2026 Results: Net Loss Widens

Cardiff Lexington Corporation's Q2 2026 Form 10-Q reveals a significant increase in net loss to $2.48 million, driven by declining revenues and rising operating expenses.

Summary

• Cardiff Lexington Corporation reported a net loss of $2,478,906 for the three months ended June 30, 2026, an increase from a net loss of $1,226,395 in the same period of 2025.
• Total revenue for the second quarter of 2026 decreased by 22.57% to $2,159,557 compared to $2,789,007 in the second quarter of 2025.
• Cost of sales as a percentage of revenue increased from 39.22% to 45.25%, leading to a decrease in gross profit margin from 60.78% to 54.75%.
• Selling, general, and administrative expenses increased significantly by 37.72% to $1,359,766 for the three months ended June 30, 2026.
• The company has an accumulated deficit of $85,617,319 as of June 30, 2026, and negative cash flow from operations of $668,649 for the six months ended June 30, 2026, raising substantial doubt about its ability to continue as a going concern.
• The company is actively seeking additional capital infusions to fund operations and pursue acquisitions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, declining revenues, and substantial operating expenses, indicating ongoing financial challenges and a precarious going concern status.

Positives

• The company's healthcare segment continues to generate revenue, although it has seen a decline.
• The company has a substantial net operating loss carryforward of approximately $24.4 million, which could offset future taxable income.
• The company is actively pursuing prospective investors to raise capital.

Negatives

• Net loss for the three months ended June 30, 2026, increased by 102.13% to $2,478,906 compared to the prior year period.
• Revenue for the three months ended June 30, 2026, decreased by 22.57% to $2,159,557 compared to the prior year period.
• Gross profit margin decreased from 60.78% to 54.75% for the three months ended June 30, 2026.
• Selling, general, and administrative expenses increased by 37.72% to $1,359,766 for the three months ended June 30, 2026.
• The company has an accumulated deficit of $85,617,319 as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern due to sustained operating losses and negative cash flow from operations.
• Several loan agreements, including those with related parties, are in default as of June 30, 2026.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional cash infusions, with no assurance of success.
• Failure to raise sufficient funds may require curtailment of operating plans, cost reductions, or cessation of operations.
• The lawsuit filed by former Chairman Daniel R. Thompson could have a material adverse effect on the company's business, financial condition, results of operations, cash flows, and prospects.
• The company's revenue realization rate is subject to negotiation and settlement outcomes, which are outside its control.
• The company has significant convertible debt with complex features and derivative liabilities, which introduce financial risks and valuation uncertainties.
• The company's operations are heavily reliant on its healthcare subsidiary, Nova Ortho and Spine, LLC, making it vulnerable to industry-specific risks.

Future Outlook

The company's ability to continue as a going concern is dependent on securing additional capital. Management is actively seeking prospective investors and believes raising capital will fund cash flow shortfalls and support new acquisitions. However, there is no assurance that sufficient capital will be obtained on acceptable terms. Failure to secure funding may necessitate curtailing operations or even cessation of operations.

Management Comments

• Management believes that raising capital will allow the Company to fund its cash flow shortfalls and pursue new acquisitions.
• There can be no assurance that the Company will be able to obtain sufficient capital from debt or equity transactions or from operations in the necessary time frame or on terms acceptable to it.
• Should the Company be unable to raise sufficient funds, it may be required to curtail its operating plans. In addition, increases in expenses may require cost reductions.
• No assurance can be given that the Company will be able to operate profitably on a consistent basis, or at all, in the future.
• Should the Company not be able to raise sufficient funds, it may cause cessation of operations.

Industry Context

StockSavvy.ai notes that the healthcare services industry, particularly in specialized areas like orthopedics and spine care, is competitive and subject to regulatory changes and reimbursement pressures. Cardiff Lexington's focus on plaintiff-related care and an uninsured market presents a unique risk profile, heavily dependent on successful litigation outcomes and settlement realization rates.

Comparison to Industry Standards

• The healthcare services industry typically aims for strong revenue growth and profitability. Cardiff Lexington's declining revenue and increasing net loss are contrary to typical industry performance.
• Gross margins in healthcare services can vary, but a decline from 60.78% to 54.75% is a significant negative trend.
• Companies in this sector often maintain healthy cash reserves or access to credit lines to manage operations; Cardiff Lexington's low cash balance ($217,654) and reliance on external financing highlight a weaker liquidity position compared to industry peers.
• The significant increase in SG&A expenses as a percentage of revenue (from 35.40% to 62.97%) is concerning and suggests potential inefficiencies or escalating operational costs not being offset by revenue growth.

Legal Proceedings

• Daniel R. Thompson, former Chairman, filed a lawsuit alleging breach of contract, breach of good faith and fair dealing, and unjust enrichment, seeking unspecified damages and declaratory relief regarding compensation and a conversion agreement. The court dismissed the case without prejudice for mediation.
• The company intends to vigorously defend against any refiled claims by Mr. Thompson, though the outcome is uncertain and could materially affect the business.

Related Party Transactions

• On June 30, 2026, issued an unsecured promissory note of $233,333 to Daniel Thompson (former Chairman) to resolve accrued compensation obligations.
• On March 6, 2026, issued an unsecured promissory note of $116,667 to Daniel Thompson to resolve accrued compensation obligations.
• On March 6, 2026, cancelled $2,352,994 in deferred compensation owed to Daniel Thompson in exchange for 588,249 shares of common stock.
• On January 29, 2026, cancelled $2,365,242 in deferred compensation owed to Alex Cunningham (CEO) in exchange for 556,528 shares of common stock.
• On December 21, 2025, issued promissory notes totaling $1,085,703 for bonuses earned by employees, including notes to Alex Cunningham ($460,000), Matthew Shafer ($122,550), and Daniel Thompson ($460,000). These notes are in default as of June 30, 2026.
• Amounts due from previous owners of Edge View Properties, Inc. (current managers) totaling $4,979 as of June 30, 2026.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances and the risk of the company's inability to continue as a going concern.
• Creditors and lenders face increased risk due to loan defaults and the company's precarious financial position.
• Employees may be impacted by potential cost reductions or operational curtailments if capital is not raised.
• Suppliers may face delayed payments or increased credit risk due to the company's liquidity challenges.

Next Steps

• Continue to seek additional capital infusions from prospective investors.
• Pursue new acquisitions if capital is successfully raised.
• Potentially curtail operating plans or implement cost reductions if sufficient funds are not raised.
• Engage in mediation for 60 days regarding the lawsuit filed by Daniel R. Thompson before potentially refiling.
• The company may employ methods to accelerate cash settlement of accounts receivable by accepting lower settlement amounts.

Key Dates

Recommendation

The company exhibits significant financial distress, including widening net losses, declining revenues, a substantial accumulated deficit, and a serious going concern issue. The ongoing litigation and reliance on external capital infusions without assurance of success further elevate the risk profile, making it a sell recommendation.

Keywords

Healthcare Services, Orthopedics, Spine Care, Medical Billing, Convertible Notes, Derivative Liabilities, Going Concern, Revenue Decline